There are about 10460 clinical studies being (or have been) conducted in Australia. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Decarboxylase Inhibitor to L-dopa Responsive Parkinson's Disease Patients
The goal of this clinical trial is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time.
This study evaluates the long-term safety and tolerability of tezacaftor in combination with ivacaftor (TEZ/IVA) in participants with cystic fibrosis (CF) aged 6 years and older, homozygous or heterozygous for the F508del mutation.
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
A pterygium is a wing-shaped, benign tissue growth which forms on the surface of the conjunctiva and grows towards the cornea. It can eventually lead to vision impairment. The precise cause of pterygium formation is unknown but new blood vessel growth and fibroblastic structures are characteristics of the disease. AG-86893 is an eye drop being developed to treat hyperemia (redness) and growth of the pterygium. Hypothesis 1. AG-86893 dosed three times daily for 28 consecutive days has an acceptable safety profile as measured by the incidence and severity of adverse events (AEs) compared with vehicle 2. At least 1 concentration of AG-86893 is effective, as measured by the mean change from baseline in conjunctival hyperemia (redness), compared with vehicle
The Asthma First Aid Management for School Staff eBook has been developed for the purpose of providing a multimedia self-directed training resource for school staff. The eBook will be accessible to both primary and secondary school staff; it has the advantage over conventional face to face training in that it can be used for learning when convenient, regardless of geographical location. The eBook has been designed to provide school staff with an alternative training option in contrast to a structured time scheduled face to face asthma first aid management training session. The content of the eBook is based on the information from the current Sydney Children's Hospital, Aiming for Asthma Improvement in Children "School Champion Asthma Management Program" (SCAMP) face to face training course. This study has been designed to determine the effectiveness of the eBook in meeting the asthma first aid management training needs of school staff, prior to its implementation and uploading to the Apple iBook store where it will be freely available to school staff internationally. The study will involve school staff being randomized into one of the following two training groups: Group 1 - a three hour face to face School Champion Asthma Management Program training session (Standard training; control group) Group 2 - completion of the self-directed Asthma First Aid Management for School Staff eBook (Technology assisted learning) The school staff will be required to complete pre and post training validated asthma knowledge questionnaires which will measure improvements in knowledge and confidence. In addition, demographic data will be collected. The researchers hypothesize that the eBook will provide school staff with an alternative mode of training that will effectively increase school staff asthma management knowledge and confidence. We aim to investigate if this training is superior to the current three hour face to face School Champion Asthma Management Program training.
This study will determine whether the Medibio Depression Diagnostic Aid exceeds minimally acceptable thresholds for sensitivity and sensitivity in cases with a current depression episode and non-depressed controls.
This study will look at how a known study medicine N8-GP works in previously N8-GP treated people with haemophilia A. The aim is to look at how N8-GP works during regular use. Participants will get N8-GP. N8-GP has been tested in more than 200 people with haemophilia A for several years. Participants will get an injection of N8-GP into a blood vessel, one, two or three times weekly. Participants will get more doses if they bleed or if they will need a surgery. The study will last for about 2 years. Participants will have at least 9 visits with the study doctor. If participants agree to be in this study, they will get their first injection (in this study) at the first visit. Participants will also get an injection at visit 3, 5 and 7. Participants will be trained to give all other injections themselves. Participants must not use any clotting factors other than N8-GP or any anticoagulants (blood thinners) during the study.